Skip to main content

Table 1 Comparison of IBD patients with and without CDI identified by laboratory dataset and by hospitalization admission and discharge database (DAD)

From: Effect of clinical versus administrative data definitions on the epidemiology of C. difficile among hospitalized individuals with IBD: a population-based cohort study

 

Laboratory dataset

DAD

IBD patients with CDI (n = 108)

Matched IBD patients without CDI (n = 531)

p-value

IBD patients with CDI (n = 110)

Matched IBD patients without CDI (n = 539)

p-value

Age median (IQR)

55.5(34–75)

55 (34–75)

 

60 (40–75)

59 (40–74)

 

% CD

51

51

 

46

47

 

% Male

44

44

 

47

48

 

Use 1 year prior

      

5-ASA use (%)

47.2

37.9

0.084

51.8

39.2

0.015

Thiopurine use (%)

19.4

16.4

0.48

16.4

13.5

0.45

Anti-TNF use (%)

7.4

8.7

0.85

10.9

8.0

0.35

Corticosteroid use (%)

45.4

22.6

< 0.001

40.9

22.3

 < 0.001

Use 3 month prior

      

Any antibiotic use (%)

50.0

23.5

< 0.001

50.9

19.8

 < 0.001

Ciprofloxacin use (%)

16.7

6.4

0.002

16.4

5.2

 < 0.001

Metronidazole use (%)

17.6

4.7

< 0.001

16.4

3.3

 < 0.001

Clindamycin use (%)

Data too sparse to report N < 6

0.031

Data too sparse to report N < 6

0.016

Hospitalization in the prior year (%)

62.0

31.1

< 0.001

63.6

31.5

< 0.001

Surgery (%)

23.2

23.9

0.90

20.0

25.1

0.28

Charlson Comorbidity index score (%)

  

0.002

  

0.004

 0

49.1

61.6

 

42.7

59.0

 

 1

16.7

19.4

 

20.0

19.1

 2

21.3

9.6

 

17.3

9.5

 3+

13.0

9.4

 

20.0

12.4

Ambulatory care (%)

  

< 0.001

  

< 0.001

Lowest quartile

11.1

29.8

 

10.0

30.2

 2nd quartile

15.7

25.8

 

14.6

25.1

 3rd quartile

34.3

22.2

 

34.6

23.4

 Highest quartile

38.9

22.2

 

40.9

21.3

  1. aAmbulatory care frequency quartiles: Quartile 1 0–8, Quartile 2 9–16, Quartile 3 17–27, Quartile 4 28+
  2. *Bolded p-values are statistically significant